Vertex Pharmaceuticals reported $3.71B in Trade Creditors for its fiscal quarter ending in September of 2026.





Trade Creditors Change Date
AbbVie USD 33.3B 29.71B Jun/2026
Acadia Pharmaceuticals USD 16.33M 28.24M Sep/2026
Agios Pharmaceuticals USD 19.93M 3.58M Sep/2026
Alnylam Pharmaceuticals USD 135.4M 27.38M Sep/2026
Amgen USD 20.83B 17.97B Sep/2026
Arrowhead Research USD 30.15M 2.37M Sep/2026
Biogen USD 430.3M 26.4M Sep/2026
BioMarin Pharmaceutical USD 946.11M 32.44M Sep/2026
Bristol-Myers Squibb USD 4.63B 470M Sep/2026
Gilead Sciences USD 934M 260M Sep/2026
Incyte USD 235.37M 1.16B Sep/2026
Insmed USD 84.3M 9.75M Sep/2026
Ionis Pharmaceuticals USD 27.11M 20.59M Sep/2026
J&J USD 9.32B 94M Sep/2026
Merck USD 5.03B 1.2B Sep/2026
Moderna USD 259M 92M Sep/2026
Neurocrine Biosciences USD 754.1M 612.1M Sep/2026
Novartis USD 4.24B 15M Sep/2026
Pfizer USD 4.07B 511M Sep/2026
PTC Therapeutics USD 41.59M 1.14M Sep/2026
Puma Biotechnology USD 6.39M 962K Sep/2025
Regeneron Pharmaceuticals USD 1.14B 19M Sep/2026
Roche Holding CHF 5.54B 237M Jun/2026
Sangamo BioSciences USD 10.74M 7.46M Jun/2025
Sanofi EUR 24.55B 957M Sep/2026
Sarepta Therapeutics USD 45.7M 5.28M Sep/2026
Ultragenyx Pharmaceutical USD 45M 6M Sep/2026
United Therapeutics USD 520.2M 22.4M Sep/2026
Vertex Pharmaceuticals USD 3.71B 99.2M Sep/2026